Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA

JUHA ONATSU, MIKKO TAINA, PIRJO MUSTONEN, MARJA HEDMAN, ANTTI MUURONEN, OTSO ARPONEN, MIIKA KORHONEN, PEKKA JÄKÄLÄ, RITVA VANNINEN and KARI PULKKI
In Vivo May 2017, 31 (3) 381-386;
JUHA ONATSU
1Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Juha.Onatsu{at}kuh.fi
MIKKO TAINA
2Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PIRJO MUSTONEN
3Department of Cardiology, Keski-Suomi Central Hospital, Jyväskylä, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARJA HEDMAN
2Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANTTI MUURONEN
2Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OTSO ARPONEN
2Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MIIKA KORHONEN
2Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PEKKA JÄKÄLÄ
1Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland
4Unit of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RITVA VANNINEN
2Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland
5Department of Clinical Radiology, University of Eastern Finland, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KARI PULKKI
6Department of Clinical Chemistry, University of Eastern Finland, Kuopio, Finland
7Eastern Finland Laboratory Centre, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 31 no. 3 381-386
PMID 
28438866

Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received January 14, 2017
  • Revision received February 26, 2017
  • Accepted March 1, 2017
  • Published online April 24, 2017.

Copyright & License 
Copyright © 2017 The Author(s). Published by the International Institute of Anticancer Research.

Author Information

  1. JUHA ONATSU1⇑,
  2. MIKKO TAINA2,
  3. PIRJO MUSTONEN3,
  4. MARJA HEDMAN2,
  5. ANTTI MUURONEN2,
  6. OTSO ARPONEN2,
  7. MIIKA KORHONEN2,
  8. PEKKA JÄKÄLÄ1,4,
  9. RITVA VANNINEN2,5 and
  10. KARI PULKKI6,7
  1. 1Department of Neurology, NeuroCenter, Kuopio University Hospital, Kuopio, Finland
  2. 2Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland
  3. 3Department of Cardiology, Keski-Suomi Central Hospital, Jyväskylä, Finland
  4. 4Unit of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
  5. 5Department of Clinical Radiology, University of Eastern Finland, Kuopio, Finland
  6. 6Department of Clinical Chemistry, University of Eastern Finland, Kuopio, Finland
  7. 7Eastern Finland Laboratory Centre, Kuopio, Finland
  1. Correspondence to: Juha Onatsu, MD, Department of Neurology, NeuroCenter, Kuopio University Hospital, P. O. BOX 100, 70029 Kuopio, Finland. Tel: +358 447174856, e-mail: Juha.Onatsu{at}kuh.fi
View Full Text

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

In Vivo
Vol. 31, Issue 3
May-June 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA
JUHA ONATSU, MIKKO TAINA, PIRJO MUSTONEN, MARJA HEDMAN, ANTTI MUURONEN, OTSO ARPONEN, MIIKA KORHONEN, PEKKA JÄKÄLÄ, RITVA VANNINEN, KARI PULKKI
In Vivo May 2017, 31 (3) 381-386;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA
JUHA ONATSU, MIKKO TAINA, PIRJO MUSTONEN, MARJA HEDMAN, ANTTI MUURONEN, OTSO ARPONEN, MIIKA KORHONEN, PEKKA JÄKÄLÄ, RITVA VANNINEN, KARI PULKKI
In Vivo May 2017, 31 (3) 381-386;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Limitations
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events
  • Google Scholar

More in this TOC Section

  • Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer
  • Impact of Donor Cirrhosis Outcome Risk Estimator (CORE) Score on Recipient Outcomes Following Living-donor Liver Transplantation
  • The Clinical Impact of Textbook Outcome in Patients With Stage 1 Gastric Cancer Who Received Laparoscopy-assisted Gastrectomy or Robotic-assisted Gastrectomy
Show more Clinical Studies

Keywords

  • suPAR
  • ischemic stroke
  • inflammation
  • mortality
  • cardioembolic
In Vivo

© 2026 In Vivo

Powered by HighWire